OSI-906

DRUG13 trials

Sponsors

Astellas Pharma Inc, University of Colorado, Denver, SCRI Development Innovations, LLC, Vanderbilt-Ingram Cancer Center, M.D. Anderson Cancer Center

Conditions

Adrenocortical CarcinomaAdvanced Hepatocellular Carcinoma (HCC)Advanced Solid TumorsColorectal CancerHead and Neck CancerHormone-sensitive Metastatic Breast CancerMetastatic Colorectal CancerNSCLC

Phase 1

Study of Intermittent OSI-906 Dosing

CompletedNCT00514306

Astellas Pharma IncAdvanced Solid Tumors

Start: 2007-07-05End: 2010-09-20Updated: 2024-11-20

Study of Continuous OSI-906 Dosing

CompletedNCT00514007

Astellas Pharma IncAdvanced Solid Tumors

Start: 2007-06-18End: 2012-03-19Updated: 2024-11-20

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

CompletedNCT00739453

Astellas Pharma IncAdvanced Solid Tumors

Start: 2008-10-23End: 2012-03-03Updated: 2024-11-20

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

CompletedNCT00889382

Astellas Pharma IncOvarian Cancer, Solid Tumors

Start: 2009-08-05End: 2014-08-25Updated: 2024-11-20

OSI-906 and Irinotecan in Patients With Advanced Cancer

TerminatedNCT01016860

University of Colorado, DenverColorectal Cancer

Start: 2009-12-31End: 2013-04-30Updated: 2013-10-21

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

CompletedNCT01154335

SCRI Development Innovations, LLCMetastatic Colorectal Cancer

Start: 2010-07-31End: 2013-05-31Updated: 2022-05-03

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

CompletedNCT01529684

Astellas Pharma Global Development, Inc.Advanced Solid Tumors, Pharmacokinetics of 14C-OSI-906

Start: 2012-03-19End: 2013-02-20Updated: 2024-11-07

Phase 2

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

TerminatedNCT01101906

Astellas Pharma IncAdvanced Hepatocellular Carcinoma (HCC)

Start: 2011-01-10End: 2011-12-28Updated: 2024-11-20

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

CompletedNCT01186861

Astellas Pharma IncNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Start: 2011-03-04End: 2015-03-11Updated: 2025-11-18

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

TerminatedNCT01205685

Vanderbilt-Ingram Cancer CenterHormone-sensitive Metastatic Breast Cancer

Start: 2010-05-31End: 2011-07-31Updated: 2012-09-11

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

CompletedNCT01221077

Astellas Pharma IncNon Small Cell Lung Cancer, NSCLC

Start: 2011-04-08End: 2014-09-01Updated: 2025-11-18

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

WithdrawnNCT01427205

M.D. Anderson Cancer CenterHead and Neck Cancer

Start: 2013-06-30Updated: 2013-04-05

Phase 3

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

CompletedNCT00924989

Astellas Pharma IncAdrenocortical Carcinoma

Start: 2009-12-01End: 2012-10-08Updated: 2024-11-20

Related Papers

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.

2018-02-1431 citations

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

2015-03-18246 citations

International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).

Journal of Clinical Oncology2014-05-205 citations